(1R,3aS,3bS,6aR)-5-methyl-1-phenyl-3a,3b,6,6a-tetrahydro-3H-2-oxa-7a-aza-cyclopenta[a]pentalen-7-one | 597569-37-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1R,3aS,3bS,6aR)-5-methyl-1-phenyl-3a,3b,6,6a-tetrahydro-3H-2-oxa-7a-aza-cyclopenta[a]pentalen-7-one
• 英文别名: (1S,2S,5R,8R)-10-methyl-5-phenyl-4-oxa-6-azatricyclo[6.3.0.02,6]undec-10-en-7-one
• CAS: 597569-37-4
• 化学式: C₁₆H₁₇NO₂
• 分子量: 255.316
• InChiKey: BPNPHABRCKCWIO-DSJMHWKBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1R,3aS,3bS,6aR)-5-methyl-1-phenyl-3a,3b,6,6a-tetrahydro-3H-2-oxa-7a-aza-cyclopenta[a]pentalen-7-one 在 钯 氢气 、 title compound 作用下， 以 乙醇 为溶剂， 反应 1.5h， 生成 (1R,3aS,3bS,6aR)-5-methyl-1-phenyl-3a,3b,4,5,6,6a-hexahydro-2-oxa-7a-aza-cyclopenta[a]pentalen-7-one
  参考文献：
  名称：

  3-aza-bicyclo[3.3.0]octane compounds

  摘要：

  本发明涉及式(I)的3-aza-bicyclo[3.3.0]辛烷衍生物，其中R1、R2、R3和A如描述中所述，并且它们作为促进睡眠激素受体拮抗剂的用途。

  公开号：

  US08106215B2
• 作为产物：
  描述：

  2-(三甲基硅甲基)烯丙基乙酸酯 、 (3R,7aS)-3-phenyl-3,7a-dihydro-1H-pyrrolo[1,2-c]oxazol-5-one 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 以9%的产率得到(1S,2S,5R,8R)-10-methylidene-5-phenyl-4-oxa-6-azatricyclo[6.3.0.02,6]undecan-7-one
  参考文献：
  名称：

  [3+2] Cycloaddition of trimethylenemethane (TMM) to α,β-unsaturated γ-lactam. Preparation of 5,5-fused proline surrogates

  摘要：

  Unsaturated lactam derived from (S)-pyroglutaminol undergoes a totally stereoselective cycloaddition reaction with (2-(acetoxymethyl)-3-allyl)trimethylsilane in the presence of Pd(P(OiPr)(3))(4) in refluxing toluene. This step was efficiently used to introduced the 5,5-fused framework desired for the preparation of novel proline surrogates. (C) 2003 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(03)01191-2

文献信息

• [EN] 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS<br/>[FR] COMPOSÉS 3-AZA-BICYCLO[3.3.0]OCTANE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009004584A1

  公开（公告）日：2009-01-08

  The invention relates to 3-aza-bicyclo[3.3.0]octane derivatives of the formula (I) wherein R1, R2, R3, and A are as described in the description and their use as orexin receptor antagonists.

  这项发明涉及式(I)的3-aza-bicyclo[3.3.0]辛烷衍生物，其中R1、R2、R3和A如描述中所述，并且它们作为促进睡眠的受体拮抗剂的用途。
• 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS
  申请人：Aissaoui Hamed

  公开号：US20100184808A1

  公开（公告）日：2010-07-22

  The invention relates to 3-aza-bicyclo[3.3.0]octane derivatives of the formula (I) wherein R 1 , R 2 , R 3 , and A are as described in the description and their use as orexin receptor antagonists.

  本发明涉及3-aza-bicyclo [3.3.0]辛烷衍生物，其化学式为(I)，其中R1，R2，R3和A如说明书所述，并将其用作促进醒觉素受体拮抗剂。
• US8106215B2
  申请人：——

  公开号：US8106215B2

  公开（公告）日：2012-01-31
• [3+2] Cycloaddition of trimethylenemethane (TMM) to α,β-unsaturated γ-lactam. Preparation of 5,5-fused proline surrogates
  作者：Edwin Jao、Stephane Bogen、Anil K Saksena、Viyyoor Girijavallabhan

  DOI：10.1016/s0040-4039(03)01191-2

  日期：2003.6

  Unsaturated lactam derived from (S)-pyroglutaminol undergoes a totally stereoselective cycloaddition reaction with (2-(acetoxymethyl)-3-allyl)trimethylsilane in the presence of Pd(P(OiPr)(3))(4) in refluxing toluene. This step was efficiently used to introduced the 5,5-fused framework desired for the preparation of novel proline surrogates. (C) 2003 Published by Elsevier Science Ltd.
• 3-aza-bicyclo[3.3.0]octane compounds
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：US08106215B2

  公开（公告）日：2012-01-31

  The invention relates to 3-aza-bicyclo[3.3.0]octane derivatives of the formula (I) wherein R1, R2, R3, and A are as described in the description and their use as orexin receptor antagonists.

  本发明涉及式(I)的3-aza-bicyclo[3.3.0]辛烷衍生物，其中R1、R2、R3和A如描述中所述，并且它们作为促进睡眠激素受体拮抗剂的用途。